Adverum Biotechnologies, Inc. (ADVM) News

Adverum Biotechnologies, Inc. (ADVM): $0.69

0.03 (+4.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter ADVM News Items

ADVM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ADVM News From Around the Web

Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On December 1, 2022, Adverum granted a new employee a stock option to purchase 200,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is m

Yahoo | December 6, 2022

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocul

Yahoo | November 10, 2022

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of participants supplemental injection free over two years across the 6x10^11 (6E11) and 2x10^11 (2E11) doses, respectively, regardless of

Yahoo | November 4, 2022

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California. End of stu

Yahoo | October 27, 2022

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision outcomes, as well as decreasing treatment burden by an 81-98% reduction in mean annualized anti-VEGF injections - The 2x10^11 vg/eye (2E11) dose meaningfully reduced fluid volume, including a 93% reduction in intraretinal (IRF) and 55% reduction in subretinal fluid (SRF) from baseline to week 48 -

Yahoo | September 30, 2022

Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference

REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Richard Beckman, M.D., chief medical officer of Adverum Biotechnologies, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET. The on-demand webcast corporate presentation may be

Yahoo | September 27, 2022

Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under Events and Pr

Yahoo | September 23, 2022

Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | September 23, 2022

Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day a

Yahoo | September 23, 2022

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Yahoo | September 15, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5408 seconds.